Oncology Nursing Drug Handbook at Meripustak

Oncology Nursing Drug Handbook

Books from same Author: Wilkes G M

Books from same Publisher: Jones And Bartlett

Related Category: Author List / Publisher List


  • Price: ₹ 6266.00/- [ 45.00% off ]

    Seller Price: ₹ 3446.00

Sold By: Store4Doctors      Click for Bulk Order

Offer 1: Get 45.00 % + Flat ₹ 75 discount on shopping of ₹ 500 [Use Code: MPSTK75]

Offer 2: Get 45.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 45.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Free Shipping Available



Click for International Orders
  • Provide Fastest Delivery

  • 100% Original Guaranteed
  • General Information  
    Author(s)Wilkes G M
    PublisherJones And Bartlett
    ISBN9780763739232
    Pages1211
    BindingSoftbound
    LanguageEnglish
    Publish YearDecember 2005

    Description

    Jones And Bartlett Oncology Nursing Drug Handbook by Wilkes G M

    2006 Oncology Nursing Drug Handbook is a comprehensive nursing resource for assessment, intervention, and patient education in the administration of oncology drugs. This text reviews drug information from the nurse's point of view, and helps the nurse focus on minimizing toxicity. This essential reference provides valuable information on effective symptom management and chemotherapy administration for the oncology nurse. Updated annually, the 2006 edition includes the following new drugs: four antineoplastic agents (clofarabine, histrelin implant, paclitaxel protein bound particles for injection, TLK 286), four antimicrobial agents (micafungin, rifaximin, gemifloxacin, tigecycline), two immunotherapy/biotherapy symptom management agents (Imiquimod 5% cream., palifermin), and eight molecularly targeted drugs (lapatanib, panitumumab, pertuzumab, sorafeni (BAY 43-9006), sunitinib malate (sutent, SU11246), temsirolimus, tipifarnib, vatalanib), and one symptom management drug (ziconotide intrathecal infusion). In addition, indications and additional toxicity data have been updated for individual drugs, such as bevacizumab, cetuximab, and gefitinib.